Tilray (NASDAQ:TLRY) and Nutra Pharma (OTCMKTS:NPHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.
This table compares Tilray and Nutra Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Tilray and Nutra Pharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tilray||$20.53 million||526.40||-$7.80 million||N/A||N/A|
|Nutra Pharma||$120,000.00||5.00||-$4.02 million||N/A||N/A|
Nutra Pharma has lower revenue, but higher earnings than Tilray.
Institutional & Insider Ownership
0.8% of Tilray shares are owned by institutional investors. Comparatively, 0.0% of Nutra Pharma shares are owned by institutional investors. 20.9% of Nutra Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Tilray and Nutra Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Tilray presently has a consensus price target of $135.67, suggesting a potential upside of 16.92%. Given Tilray’s higher probable upside, analysts plainly believe Tilray is more favorable than Nutra Pharma.
Tilray beats Nutra Pharma on 7 of the 10 factors compared between the two stocks.
Tilray Company Profile
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Nutra Pharma Company Profile
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Nyloxin, a topical therapy for chronic pain in horses. It is also developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes; RPI-78 for pain and arthritis; and RPI-70 for pain. The company has a collaboration agreement with the International Security Group to develop nerve agent counter measures. Nutra Pharma Corp. was founded in 2000 and is based in Coral Springs, Florida.
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.